Markets India
Four Indian drug manufacturing stocks surged over 60% in six months, driven by strong quarterly results and target price upgrades. Laurus Labs led the rally with an 88.64% gain.
Pharmaceutical Contract Development and Manufacturing Organisation (CDMO) companies saw a sharp rise in their stock prices over the past six months, fueled by optimism around recent financial performance and analyst confidence. Among them, Laurus Labs was the standout performer with an 88.64% increase, closing at ₹2,395.10 on BSE. Gland Pharma followed closely behind with an 80.36% surge to ₹3,307.50 per share, while Divi’s Laboratories rose 72.35%, surpassing its target price of ₹11,450 at a closing value of ₹11,450.
The rally reflects growing investor confidence in the CDMO sector's ability to meet rising demand for drug manufacturing services amid complex regulatory environments and supply chain challenges. Motilal Oswal set target prices of ₹2,830 for Laurus Labs and ₹3,690 for Gland Pharma, while ICICI Securities and Motilal Oswal Financial Services both targeted Divi’s Laboratories at ₹11,450 and ₹11,110 respectively. Piramal Pharma also saw a 38.65% gain to close at ₹245.20 per share.
Analysts believe the strong quarterly results have bolstered market sentiment for CDMO companies, signaling optimism about their growth potential and profitability in an evolving industry landscape.
The second-quarter results for FY 26-27 are expected to further influence investor confidence and stock price movements.
Strong quarterly performance has driven a six-month rally in CDMO stocks, but future gains will depend on upcoming financial reports and sustained demand for manufacturing services.
Topics: Pharmaceuticals, Stock Market, Rising Demand For CDMO Services, Fortune 500 Companies, Laurus Labs, Gland Pharma, Divi'S Laboratories, Piramal Pharma, BSE Stock Prices, Motilal Oswal Target Price
#CDMOStockRally #IndianPharmaGrowth #LaurusLabsSurge #PiramalPharmaceuticals #BSEMarketTrends
Source: LiveMint
Post a Comment
Post a Comment